Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Misdiagnosis led to unnecessary treatment due to a genetic mutation affecting thyroid hormone resistance.

Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.

Both vaginal testosterone cream and Estring effectively manage vaginal dryness in women with early-stage breast cancer on aromatase inhibitors.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.

A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.

Cinacalcet may help treat hereditary vitamin D resistant rickets safely.

Adding a second method to PROTACs could improve cancer treatment.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Tofacitinib may effectively treat folliculitis decalvans.

The combination therapy was effective and well-tolerated, especially in young patients.

Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.

SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe side effects.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

Betamethasone valerate foam is more effective and safe for treating mild-to-moderate alopecia areata than betamethasone dipropionate lotion.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.